Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Oct 23;19(1):205.
doi: 10.1186/s12931-018-0905-x.

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis

Giovanni Sotgiu  1 , Stefano Aliberti  2   3 , Andrea Gramegna  4   5 , Marco Mantero  4   5 , Marta Di Pasquale  4   5 , Federica Trogu  1 , Laura Saderi  1 , Francesco Blasi  4   5
Affiliations
Meta-Analysis

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis

Giovanni Sotgiu et al. Respir Res. .

Abstract

Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia.

Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational studies.

Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including MDR pathogens.

Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.

Keywords: CAP; HAP; HCAP; MRSA; Safety; Stewardship; VAP.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow-chart of the systematic review
Fig. 2
Fig. 2
Efficacy of ceftaroline in the overall pneumonia (including CAP, VAP, HCAP, HAP)
Fig. 3
Fig. 3
Clinical success in CAP subjects treated with ceftaroline
Fig. 4
Fig. 4
Clinical success in HAP/VAP/HCAP subjects treated with ceftaroline
Fig. 5
Fig. 5
Effect of ceftaroline on clinical cure
Fig. 6
Fig. 6
Clinical and microbiological response rates in subjects with Streptococcus pneumoniae treated with ceftaroline
Fig. 7
Fig. 7
Clinical cure rates in subjects with MDR Streptococcus pneumoniae treated with ceftaroline at TOC visit
Fig. 8
Fig. 8
Clinical and microbiological response rates in subjects with MSSA treated with ceftaroline
Fig. 9
Fig. 9
Clinical and microbiological response rates in subjects with MRSA treated with ceftaroline
See this image and copyright information in PMC

References

    1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–1416. doi: 10.1016/S0140-6736(13)60222-6. - DOI - PMC - PubMed
    1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–250. doi: 10.1056/NEJM199701233360402. - DOI - PubMed
    1. Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S48–S53. doi: 10.1086/653049. - DOI - PubMed
    1. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI. GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016;16(12):1364–1376. doi: 10.1016/S1473-3099(16)30267-5. - DOI - PubMed
    1. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax. 2013;68(11):997–999. doi: 10.1136/thoraxjnl-2013-203384. - DOI - PubMed

MeSH terms